655 related articles for article (PubMed ID: 33815296)
1. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
2. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome.
Barrea L; Annunziata G; Muscogiuri G; Di Somma C; Laudisio D; Maisto M; de Alteriis G; Tenore GC; Colao A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30551613
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency.
Qing L; Wei R; Chan L; Xiaoya Z; Xin X
J Endocrinol Invest; 2017 Jun; 40(6):653-661. PubMed ID: 28233232
[TBL] [Abstract][Full Text] [Related]
4. Visceral Adiposity Index (VAI) in Children and Adolescents with Obesity: No Association with Daily Energy Intake but Promising Tool to Identify Metabolic Syndrome (MetS).
Vizzuso S; Del Torto A; Dilillo D; Calcaterra V; Di Profio E; Leone A; Gilardini L; Bertoli S; Battezzati A; Zuccotti GV; Verduci E
Nutrients; 2021 Jan; 13(2):. PubMed ID: 33525454
[TBL] [Abstract][Full Text] [Related]
5. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
6. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
[TBL] [Abstract][Full Text] [Related]
7. Can Visceral Adiposity Index Serve as a Simple Tool for Identifying Individuals with Insulin Resistance in Daily Clinical Practice?
Štěpánek L; Horáková D; Cibičková Ľ; Vaverková H; Karásek D; Nakládalová M; Zapletalová J
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31470593
[No Abstract] [Full Text] [Related]
8. Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire.
Barrea L; Macchia PE; Tarantino G; Di Somma C; Pane E; Balato N; Napolitano M; Colao A; Savastano S
J Transl Med; 2015 Sep; 13():303. PubMed ID: 26376719
[TBL] [Abstract][Full Text] [Related]
9. Applicability of visceral adiposity index in predicting metabolic syndrome in adults with obstructive sleep apnea: a cross-sectional study.
Chen GP; Qi JC; Wang BY; Lin X; Zhang XB; Zhao JM; Chen XF; Lin T; Chen DD; Lin QC
BMC Pulm Med; 2016 Mar; 16():37. PubMed ID: 26931776
[TBL] [Abstract][Full Text] [Related]
10. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
Barrea L; Muscogiuri G; Pugliese G; Modica R; Laudisio D; Aprano S; Faggiano A; Colao A; Savastano S
J Transl Med; 2021 Jul; 19(1):324. PubMed ID: 34330303
[TBL] [Abstract][Full Text] [Related]
11. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease.
Vongsuvanh R; George J; McLeod D; van der Poorten D
J Hepatol; 2012 Aug; 57(2):392-8. PubMed ID: 22521350
[TBL] [Abstract][Full Text] [Related]
12. Comparison of visceral, general and central obesity indices in the prediction of metabolic syndrome in maintenance hemodialysis patients.
Zhou C; Zhan L; Yuan J; Tong X; Peng Y; Zha Y
Eat Weight Disord; 2020 Jun; 25(3):727-734. PubMed ID: 30968371
[TBL] [Abstract][Full Text] [Related]
13. Visceral Adiposity Index As a Practical Tool in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Vural Keskinler M; Mutlu HH; Sirin A; Erkalma Senates B; Colak Y; Tuncer I; Oguz A
Metab Syndr Relat Disord; 2021 Feb; 19(1):26-31. PubMed ID: 32898457
[No Abstract] [Full Text] [Related]
14. The Role of Visceral Adiposity Index Levels in Predicting the Presence of Metabolic Syndrome and Insulin Resistance in Overweight and Obese Patients.
Pekgor S; Duran C; Berberoglu U; Eryilmaz MA
Metab Syndr Relat Disord; 2019 Jun; 17(5):296-302. PubMed ID: 30932744
[No Abstract] [Full Text] [Related]
15. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Santos AP; Santos AC; Castro C; Raposo L; Pereira SS; Torres I; Henrique R; Cardoso H; Monteiro MP
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30150555
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
17. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
[TBL] [Abstract][Full Text] [Related]
18. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
19. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
